公开(公告)号：US20240252539A1

公开(公告)日：2024-08-01

申请号：US18560791

申请日：2022-05-26

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： Katy REZVANI ,  Elizabeth J. SHPALL ,  Rafet BASAR ,  Sunil ACHARYA ,  Nadima UPRETY ,  David MARIN COSTA ,  Emily ENSLEY

IPC分类号： A61K35/17 ,  A61K39/00 ,  A61K45/06 ,  A61K47/68 ,  A61P35/00 ,  C07K14/54 ,  C07K16/28 ,  C12N15/85

CPC分类号： A61K35/17 ,  A61K39/4613 ,  A61K39/4631 ,  A61K39/464411 ,  A61K39/46444 ,  A61K45/06 ,  A61K47/6829 ,  A61P35/00 ,  C07K14/5443 ,  C07K16/2833 ,  C12N15/85 ,  A61K2239/13 ,  A61K2239/21 ,  A61K2239/22

摘要： Embodiments of the disclosure include methods and compositions related to targeting of HLA-G-expressing cells with particular engineered receptors. In specific embodiments, NK cells are specifically engineered to bind HLA-G using particular chimeric antigen receptor constructs. In certain embodiments, vectors that express the HLA-G-targeting CARs also express particular a suicide gene and/or one or more particular cytokines.

公开(公告)号：US20230210902A1

公开(公告)日：2023-07-06

申请号：US17997148

申请日：2021-05-11

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： Katy REZVANI ,  Elizabeth SHPALL ,  Rafet BASAR ,  David MARIN COSTA ,  Nadima UPRETY ,  Emily ENSLEY

IPC分类号： A61P31/14 ,  A61K45/06 ,  C07K16/10 ,  A61K35/17 ,  C12N5/0783 ,  C12N15/11 ,  C12N9/22 ,  C12N15/90

CPC分类号： A61K35/17 ,  A61K45/06 ,  A61P31/14 ,  C07K16/10 ,  C12N5/0638 ,  C12N9/22 ,  C12N15/11 ,  C12N15/907 ,  C12N2310/20 ,  C12N2501/998 ,  C12N2501/2302 ,  C12N2501/2304 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2501/2321 ,  C12N2800/80

摘要： Embodiments of the disclosure includes methods of producing viral-specific therapy (VST) cells specific for the SARS-CoV-2 virus and uses of the cells. The methods may utilized peptide mixtures and stimulation of mononuclear cells using particular cytokine cocktails. The cells may also be genetically modified to lack expression of one or more endogenous genes, including one or more genes that renders the cells more effective and/or able to withstand deleterious conditions, such as the presence of glucocorticoids.

公开(公告)号：US20240325444A1

公开(公告)日：2024-10-03

申请号：US18574539

申请日：2022-07-08

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： Katy REZVANI ,  Sunil ACHARYA ,  Funda MERIC-BERNSTAM ,  Nadima UPRETY ,  Rafet BASAR ,  David MARIN COSTA

IPC分类号： A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/54 ,  C07K14/705 ,  C07K14/725 ,  C07K16/30 ,  C12N5/0783 ,  C12N9/22

CPC分类号： A61K35/17 ,  A61K39/4613 ,  A61K39/4631 ,  A61K39/464402 ,  A61P35/00 ,  C07K14/5443 ,  C07K14/7051 ,  C07K14/70578 ,  C07K16/30 ,  C12N5/0646 ,  C12N9/22 ,  A61K2239/13 ,  A61K2239/21 ,  A61K2239/38 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C12N2510/00

摘要： Embodiments of the disclosure include methods and compositions related to targeting of TROP-2-expressing cells with particular engineered receptors. In specific embodiments, NK cells are specifically engineered to bind TROP-2 using particular chimeric antigen receptor constructs. In certain embodiments, vectors that express the TROP-2-targeting CARs also express a particular suicide gene and/or one or more particular cytokines.

公开(公告)号：US20240189357A1

公开(公告)日：2024-06-13

申请号：US18552727

申请日：2022-04-14

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： Katy REZVANI ,  Elizabeth SHPALL ,  Rafet BASAR ,  May DAHER ,  Sunil ACHARYA ,  Nadima UPRETY ,  Ana Karen NUNEZ CORTES ,  Emily ENSLEY ,  David MARIN COSTA

IPC分类号： A61K35/17 ,  A61K39/00 ,  A61K45/06 ,  A61P35/00 ,  C07K14/54 ,  C07K16/28 ,  C12N5/0783 ,  C12N9/22

CPC分类号： A61K35/17 ,  A61K39/4613 ,  A61K39/4631 ,  A61K39/464429 ,  A61K39/46444 ,  A61K45/06 ,  A61P35/00 ,  C07K14/5443 ,  C07K16/2896 ,  C12N5/0646 ,  C12N9/22 ,  A61K2239/13 ,  A61K2239/17 ,  A61K2239/21 ,  A61K2239/48 ,  C12N2310/20

摘要： Embodiments of the disclosure include methods and compositions related to targeting of CD5-expressing cells with particular engineered receptors. In specific embodiments, NK cells are specifically engineered to bind the CD5 antigen using particular chimeric antigen receptor constructs. In certain embodiments, vectors that express the CD5-targeting CARs also express particular a suicide gene and/or one or more particular cytokines.

公开(公告)号：US20230383257A1

公开(公告)日：2023-11-30

申请号：US18248193

申请日：2021-10-15

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： Elizabeth SHPALL ,  Katy REZVANI ,  Bijender KUMAR ,  Mayela MENDT ,  Vahid AFSHAR-KHARGHAN ,  Rafet BASAR

IPC分类号： C12N5/078 ,  A61K35/19

CPC分类号： C12N5/0644 ,  A61K35/19 ,  C12N2506/1369 ,  C12N2502/11 ,  C12N2501/727 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/2306 ,  C12N2501/724

摘要： Embodiments of the disclosure include systems, methods, and compositions for producing megakaryocytes and platelets for recipient individuals in need thereof. The megakaryocytes and platelets are produced following co-culture of MSCs and CD34+ cells in media comprising stem cell factor, thrombopoietin, and IL-6, and wherein at least the CD34+ cells have a knock-in of HLA-E at the beta-2-microglobulin genomic locus, in specific embodiments. In some cases, ROCK inhibitors are utilized.

公开(公告)号：US20240325443A1

公开(公告)日：2024-10-03

申请号：US18290898

申请日：2022-07-22

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： Enli LIU ,  Katy REZVANI ,  Rafet BASAR ,  Bin LIU ,  David MARIN COSTA

IPC分类号： A61K35/17 ,  A61K39/00 ,  A61K39/395 ,  A61P35/00 ,  C07K14/54 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783

CPC分类号： A61K35/17 ,  A61K39/39558 ,  A61K39/4613 ,  A61K39/4632 ,  A61K39/4633 ,  A61K39/464412 ,  A61K39/464488 ,  A61K39/464489 ,  A61P35/00 ,  C07K14/5443 ,  C07K14/7051 ,  C07K14/70521 ,  C07K16/2809 ,  C07K16/30 ,  C12N5/0646 ,  C07K2317/31 ,  C07K2317/73 ,  C07K2319/02 ,  C07K2319/03 ,  C12N2510/00

摘要： Embodiments of the disclosure include methods and compositions in which NK cells are modified by the hand of man to express the T-cell receptor and CD3 co-receptor on NK cells that do not naturally express them. Such modified NK cells work effectively with bispecific or multi-specific antibodies that are tailored to comprise anti-CD3 antibodies that bind the modified NK cells, thereby triggering signaling, activation, and cytotoxicity of target cells to which the antibodies also bind. Thus, the NK cells are specifically configured to be able to work effectively with Bispecific NK cell engagers (BiKEs) as well as Bispecific T cell Engagers (BiTEs).

公开(公告)号：US20220403418A1

公开(公告)日：2022-12-22

申请号：US17756104

申请日：2020-11-25

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： Katy REZVANI ,  Rafet BASAR ,  Emily ENSLEY ,  David MARIN COSTA

IPC分类号： C12N15/90 ,  C12N5/0781 ,  A61K35/17 ,  C07K14/705 ,  C07K14/725

摘要： Embodiments of the disclosure encompass methods and compositions for producing engineered B cells. The disclosure concerns large-scale processes for producing B cells that are engineered to have disruption of expression of one or more genes using CRISPR and also express at least one heterologous antigen receptor. Specific embodiments include particular parameters for the process.

公开(公告)号：US20220378739A1

公开(公告)日：2022-12-01

申请号：US17755881

申请日：2020-11-25

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： Katy REZVANI ,  Mayra SHANLEY ,  Elizabeth SHPALL ,  David MARIN COSTA ,  Rafet BASAR ,  Hila SHAIM

IPC分类号： A61K31/395 ,  A61K35/17 ,  C12N5/0783

摘要： Embodiments of the disclosure provide methods and compositions that facilitate cancer treatment including at least because they concern therapies that circumvent the tumor microenvironment. In specific embodiments, compositions are utilized for therapy that utilize NK cells that are protected from the direct inhibition of their activity (using TGF-beta inhibitors) and/or that are indirectly protected from TGF-beta (using integrin inhibitors). In specific embodiments, the NK cells have deficient expression and/or activity for TGF-beta Receptor 2 and/or glucocorticoid receptor.

公开(公告)号：US20220401479A1

公开(公告)日：2022-12-22

申请号：US17756078

申请日：2020-11-25

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： Katy REZVANI ,  Rafet BASAR ,  Elif GOKDEMIR ,  Mayra SHANLEY

IPC分类号： A61K35/17 ,  C12N5/0783 ,  C12N15/11 ,  C12N9/22 ,  C12N15/62 ,  C12N15/90 ,  A61K38/17 ,  A61P31/12

摘要： Embodiments of the disclosure encompass methods and compositions for producing engineered T cells. The disclosure concerns large-scale processes for producing T cells that may be engineered to have disruption of expression of one or more genes using CRISPR and also express at least one heterologous antigen receptor. Specific embodiments include particular parameters for the process. The T cells may or may not be viral-specific.

公开(公告)号：US20220389383A1

公开(公告)日：2022-12-08

申请号：US17755887

申请日：2020-11-25

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： Katy REZVANI ,  Rafet BASAR ,  May DAHER ,  David MARIN COSTA

IPC分类号： C12N5/0783 ,  A61K35/17 ,  A61P35/00 ,  C12N15/113

摘要： Embodiments of the disclosure encompass methods and compositions for producing engineered natural killer (NK) cells. The disclosure concerns large-scale processes for producing NK cells that are engineered to have disruption of expression of one or more genes, such as using CRISPR, and also engineered express at least one heterologous antigen receptor. Specific embodiments include particular parameters for the process.